A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy

A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable two (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Decreased threat Later age of onset No risk association No threat association No risk association Decreased danger of eR+ BC No risk association GR79236 custom synthesis elevated overall danger No risk association improved danger of eR- BC improved threat improved threat No risk association elevated danger No danger association enhanced risk No risk association enhanced threat No danger association improved threat No risk association Decreased threat No danger association elevated general danger No danger association No risk association elevated general threat No risk association Decreased risk of eR+ BC improved danger of eR- BC No danger association Decreased risk No threat association elevated threat of eR+ No threat association No danger association Decreased risk of eR- BC Decreased threat of eR+ BC No danger association Decreased risk of eR+ No danger association No threat association elevated general risk Decreased overall threat No threat association No risk association improved risk of eR- BC improved risk elevated threat elevated danger elevated danger in eR+ earlier age of onset improved risk (A allele) earlier age of onset (C allele) Decreased threat Decreased threat increased threat Reduced survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G Ilomastat manufacturer rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B three UTR BRCA1 three UTR HPGD three UTR IGF-1R 3 UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation enhanced frequency in BRCA1 carriers/no risk association elevated risk of TNBC Decreased threat improved threat and poor survival earlier age of onset improved threat elevated danger Decreased danger Decreased overall danger No risk association Decreased danger of eR+ BC No threat association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered risk Later age of onset No danger association No threat association No danger association Decreased threat of eR+ BC No threat association increased general danger No threat association increased threat of eR- BC elevated threat increased danger No threat association enhanced danger No risk association elevated danger No danger association elevated risk No risk association increased threat No risk association Decreased threat No risk association elevated general risk No threat association No risk association enhanced general risk No risk association Decreased threat of eR+ BC increased risk of eR- BC No danger association Decreased threat No risk association elevated risk of eR+ No threat association No danger association Decreased threat of eR- BC Decreased threat of eR+ BC No danger association Decreased risk of eR+ No danger association No risk association increased all round risk Decreased general risk No danger association No danger association increased danger of eR- BC enhanced threat improved threat increased danger enhanced threat in eR+ earlier age of onset enhanced danger (A allele) earlier age of onset (C allele) Decreased risk Decreased threat enhanced danger Lowered survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 three UTR HPGD three UTR IGF-1R three UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 three UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation elevated frequency in BRCA1 carriers/no risk association elevated risk of TNBC Decreased danger improved threat and poor survival earlier age of onset improved risk elevated risk Decreased threat Decreased general danger No threat association Decreased danger of eR+ BC No danger association increas.